Aim: To evaluate the safety and metabolic effects of mesenteric visceral lipectomy in individuals with T2D.
Methods & Study Design: Eight T2D subjects (age = 52±4 y; BMI = 34.1±1.0; stable diabetes meds/weight for 3 months) underwent pre-MVL assessment including OGTT, CGM, euglycemic insulin clamp with 3H-glucose, and MRI imaging. Repeat measurements were made at 6- and 12-months post-surgery. Exclusion criteria included prior insulin/TZD use. Insulin secretion [IS], Disposition Index [DI] and Matsuda index [MI] of insulin sensitivity were calculated with standard formulae.
Results: At month 6, HbA1c decreased from 9.0% to 8.1% (p=0.08) and persisted at 8.4% at month 12 (p=0.19). CGM time-in-range increased significantly at 6 and 12 months (25% to 76%) (p<0.05). Suppression of hepatic glucose production increased at months 6 and 12 (p<0.05). Body weight and % body fat decreased slightly at month 12 (p<0.05). Insulin secretion and disposition index during OGTT increased more than 2-fold at month 6 and persisted at month 12.
G. Baskoy: None. R.M. Peterson: Consultant; Teleflex/Standard Bariatrics. J.W. Kempenich: Consultant; Intuitive Surgical. C.L. Triplitt: Speaker's Bureau; Novo Nordisk. Consultant; Eli Lilly and Company. Other Relationship; American Diabetes Association. G.D. Clarke: None. E. Cersosimo: None. M.S. Andrew: Employee; Medality Medical, Inc. A. Merovci: None. O. Lavrynenko: None. A.A. Hansis-Diarte: None. C. Solis-Herrera: Advisory Panel; Novo Nordisk, Bayer Inc. A. Chavez: None. M. Salehi: None. R.A. DeFronzo: Advisory Panel; AstraZeneca, Novo Nordisk, Boehringer-Ingelheim, Intarcia Therapeutics, Inc., Aardvark, Renalytix, Corcept Therapeutics, Alnylam Pharmaceuticals, Inc. Research Support; Boehringer-Ingelheim, AstraZeneca, 89bio, Inc., Amgen Inc., Medality, Corcept Therapeutics. Speaker's Bureau; AstraZeneca, Corcept Therapeutics, Renalytix.
Medality
